The previous studies indicated that COVID19 patients have a high prevalence of liver injury and the degree of the injury is associated with the severity of the disease (Abdulla et al., 2020; Ahmed et al., 2020; Shokri Afra et al., 2020; Ye et al., 2021), suggesting that disturbed levels of liver biomarkers, such as AST, ALT, bilirubin and albumin, could serve as prognostic tools in assessing the COVID19. This evidence concerns the gene GPT and COVID-19.